XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the activity of XRP9881 in combination with
trastuzumab.
The secondary objectives are safety and pharmacokinetic interaction